Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NHERF1 | O14745 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.51 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.45 |
| ▸ | PRSS12 | P56730 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834022 | 0.85 | NPC1 (0.55) | NHERF1 | |
| SCHEMBL6834270 | 0.80 | FLT3 (0.50) | NHERF1 | |
| SCHEMBL19554161 | 0.80 | CA2 (0.56) | SERPINE1ALB | |
| SCHEMBL6830559 | 0.80 | NHERF1 (0.45) | NHERF1SERPINE1PRSS12ALB | |
| SCHEMBL6835708 | 0.79 | CCKAR (0.51) | NHERF1 | |
| SCHEMBL6708816 | 0.78 | ALOX15 (0.44) | NHERF1ALOX15CNR2 | |
| SCHEMBL6833112 | 0.78 | KDM4E (0.57) | NHERF1 | |
| SCHEMBL6711774 | 0.78 | ALOX15 (0.43) | NHERF1ALOX15CNR2 | |
| SCHEMBL6830511 | 0.76 | NHERF1 (0.44) | NHERF1SERPINE1ALB | |
| SCHEMBL6834079 | 0.76 | NHERF1 (0.44) | NHERF1SERPINE1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | NHERF1 1142/4885ALOX15 697/4885SERPINE1 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.